NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
CHAMBERLAIN NR566 ADVANCED PHARMACOLOGY
FINAL EXAMINATION — 2026/2027
75 Questions | Advanced Pharmacology for MSN-FNP/AGPCNP | Next Generation NCLEX-Style
Total Questions: 75 | Testing Time: 120–150 Minutes | Passing Score: 75–80%
Instructions: This examination consists of 75 multiple-choice questions designed to assess advanced
pharmacology knowledge for nurse practitioner students. Each question has four answer choices (A
through D). Select the single best answer for each question. Questions cover pharmacokinetic and
pharmacodynamic principles, medication management across major organ systems, drug interactions,
adverse effects, and clinical decision-making. Use clinical judgment and evidence-based guidelines to guide
your responses. The correct answer and a detailed rationale follow each question.
1. A 55-year-old patient with hepatic cirrhosis is prescribed a medication that undergoes
extensive first-pass metabolism. Which pharmacokinetic alteration is most expected in this
patient?
A. Decreased volume of distribution leading to lower steady-state concentrations
B. Increased bioavailability due to reduced hepatic metabolism of the first-pass effect
C. Accelerated renal clearance requiring higher dosing intervals
D. Enhanced protein binding resulting in decreased free drug concentration
Correct Answer: B. Increased bioavailability due to reduced hepatic metabolism of the
first-pass effect
Rationale: First-pass metabolism occurs when a drug is extensively metabolized by the liver before
reaching systemic circulation. In hepatic cirrhosis, hepatocyte function is impaired, reducing the
first-pass effect and thereby increasing the bioavailability of the drug. This can lead to higher-than-
expected plasma concentrations and increased risk of toxicity, necessitating dosage reduction.
2. A nurse practitioner is prescribing a drug with a narrow therapeutic index. Which of the
following best defines therapeutic index (TI)?
A. The ratio of the effective dose for 99% of the population to the effective dose for 1% of the
population
B. The ratio of the median lethal dose (LD50) to the median effective dose (ED50), where a lower TI
indicates greater safety
C. The ratio of the median effective dose (ED50) to the median lethal dose (LD50), where a higher TI
indicates greater safety
D. The difference between the maximum tolerated dose and the minimum effective dose expressed in
milligrams
1
, NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
Correct Answer: C. The ratio of the median effective dose (ED50) to the median lethal
dose (LD50), where a higher TI indicates greater safety
Rationale: The therapeutic index is calculated as TD50 (or LD50) divided by ED50. A higher TI
indicates a wider margin of safety between the effective dose and the toxic dose. Drugs with a
narrow TI (e.g., warfarin, digoxin, lithium, phenytoin) require close therapeutic drug monitoring to
avoid toxicity.
3. A patient is taking a highly protein-bound drug (98% bound to albumin). A second drug
that also binds to albumin at the same site is added. What is the most likely pharmacokinetic
consequence?
A. No change in drug effect because only free drug is pharmacologically active
B. Displacement of the first drug from albumin binding sites, leading to a transient increase in free
(active) drug concentration and potential toxicity
C. Increased metabolism of the first drug due to increased hepatic blood flow
D. Decreased renal excretion of the first drug due to enhanced tubular reabsorption
Correct Answer: B. Displacement of the first drug from albumin binding sites, leading
to a transient increase in free (active) drug concentration and potential toxicity
Rationale: When two drugs compete for the same plasma protein binding site (typically albumin for
acidic drugs), the drug with higher affinity can displace the other, increasing the free (unbound)
fraction of the displaced drug. This transiently raises the pharmacologically active concentration,
potentially causing toxicity until the free drug is redistributed, metabolized, or excreted.
4. A drug has a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration with continuous dosing?
A. 12 hours (one half-life)
B. 24 hours (two half-lives)
C. 48 to 60 hours (four to five half-lives)
D. 84 hours (seven half-lives)
Correct Answer: C. 48 to 60 hours (four to five half-lives)
Rationale: Steady-state is achieved when the rate of drug administration equals the rate of
elimination. It takes approximately four to five half-lives to reach approximately 94% to 97% of
steady-state concentration. For a drug with a 12-hour half-life, steady-state is reached in 48 to 60
hours. A loading dose can achieve therapeutic levels more rapidly.
5. P-glycoprotein (P-gp) is an efflux transporter that plays a significant role in which of the
following pharmacokinetic processes?
A. Promoting drug absorption across the intestinal epithelium into systemic circulation
B. Pumping drugs out of cells back into the intestinal lumen, blood-brain barrier endothelial cells, and
renal tubules, thereby reducing bioavailability and enhancing excretion
C. Facilitating hepatic uptake of drugs for phase I metabolism
D. Enhancing protein binding of acidic drugs in the plasma compartment
2
, NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
Correct Answer: B. Pumping drugs out of cells back into the intestinal lumen, blood-
brain barrier endothelial cells, and renal tubules, thereby reducing bioavailability and
enhancing excretion
Rationale: P-glycoprotein is an ATP-dependent efflux transporter located on intestinal epithelium,
the blood-brain barrier, hepatocytes, and renal proximal tubule cells. It pumps substrates out of
cells, reducing intestinal drug absorption, limiting central nervous system penetration, and
promoting biliary and renal excretion. P-gp inhibitors (e.g., verapamil, clarithromycin) can
increase bioavailability of P-gp substrates.
6. Which of the following best describes the concept of volume of distribution (Vd)?
A. The actual physical volume within the body that a drug occupies, measured in liters
B. A theoretical pharmacokinetic parameter relating the total amount of drug in the body to the
plasma drug concentration, where a high Vd indicates extensive tissue distribution
C. The volume of blood plasma cleared of drug per unit time, expressed as mL/min
D. The concentration of drug at the site of action divided by the plasma concentration
Correct Answer: B. A theoretical pharmacokinetic parameter relating the total amount
of drug in the body to the plasma drug concentration, where a high Vd indicates
extensive tissue distribution
Rationale: Volume of distribution (Vd) is a theoretical proportionality constant defined as Vd = total
amount of drug in body / plasma drug concentration. A high Vd (>42 L in adults) suggests extensive
tissue distribution (e.g., lipophilic drugs like digoxin), while a low Vd suggests the drug remains
largely in the plasma compartment (e.g., warfarin, which is highly protein-bound).
7. A 48-year-old African American patient with type 2 diabetes mellitus and hypertension
has a blood pressure of 148/94 mmHg. According to the ACC/AHA guidelines, which of the
following first-line antihypertensive classes is most appropriate?
A. ACE inhibitor monotherapy as the sole initial agent
B. Calcium channel blocker or thiazide diuretic, either as initial monotherapy or as part of
combination therapy
C. Beta-blocker as first-line monotherapy to achieve glycemic control
D. Alpha-blocker to address both blood pressure and diabetic neuropathy symptoms
Correct Answer: B. Calcium channel blocker or thiazide diuretic, either as initial
monotherapy or as part of combination therapy
Rationale: The ACC/AHA 2017 guidelines recommend initial antihypertensive treatment with a
thiazide diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. In African American
patients, CCBs and thiazide diuretics are generally more effective as first-line agents than ACE
inhibitors or ARBs. For patients with diabetes, an ACE inhibitor or ARB is often added for renal
protection, but CCBs and thiazides are effective for BP control in this population.
8. A 62-year-old patient is started on lisinopril for hypertension. The nurse practitioner
should counsel the patient to report which of the following findings, which may indicate a
potentially serious adverse effect?
A. Mild, dry, nonproductive cough that is persistent
3
, NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
B. Swelling of the lips, tongue, or throat suggesting angioedema
C. Transient dizziness upon standing that resolves after a few minutes
D. Mild increase in serum potassium from 4.0 to 4.8 mEq/L
Correct Answer: B. Swelling of the lips, tongue, or throat suggesting angioedema
Rationale: Although a dry cough is the most common side effect of ACE inhibitors (occurring in up to
20% of patients), angioedema is the most serious and potentially life-threatening adverse effect,
occurring in 0.1% to 0.7% of patients. It involves swelling of the face, lips, tongue, and throat, which
can compromise the airway. ACE inhibitors should be discontinued immediately and the patient
should seek emergency care. Angioedema is more common in African American patients.
9. A patient with hypertension and benign prostatic hyperplasia (BPH) is prescribed
doxazosin. What is the most important safety consideration when initiating this medication?
A. Monitoring for reflex tachycardia and palpitations at therapeutic doses
B. Instructing the patient to take the first dose at bedtime to minimize the risk of first-dose
hypotension and syncope
C. Obtaining baseline liver function tests and monitoring for hepatotoxicity
D. Avoiding concurrent use with potassium-sparing diuretics due to hyperkalemia risk
Correct Answer: B. Instructing the patient to take the first dose at bedtime to minimize
the risk of first-dose hypotension and syncope
Rationale: Alpha-1 blockers (e.g., doxazosin, prazosin, terazosin) are associated with first-dose
hypotension, which can cause syncope and falls. The risk is highest with the initial dose and dose
increases. Patients should take the first dose at bedtime and rise slowly from sitting or supine
positions. Alpha-1 blockers are also used for BPH because they relax smooth muscle in the prostate
and bladder neck.
10. A 70-year-old patient with stage 2 hypertension and chronic kidney disease (CKD) stage
3a (eGFR 45 mL/min) is being evaluated for antihypertensive therapy. Which of the
following agents requires the most cautious use or dose adjustment in this patient?
A. Losartan (ARB), which provides renoprotective benefits in CKD
B. Amlodipine (CCB), which has minimal renal metabolism
C. Spironolactone (potassium-sparing diuretic), which poses a high risk of hyperkalemia in CKD
D. Lisinopril (ACE inhibitor), which should be avoided entirely in all stages of CKD
Correct Answer: C. Spironolactone (potassium-sparing diuretic), which poses a high
risk of hyperkalemia in CKD
Rationale: Spironolactone is a potassium-sparing diuretic that blocks aldosterone receptors. In
patients with CKD, the already reduced ability to excrete potassium places them at significantly
increased risk of hyperkalemia. Serum potassium and renal function must be monitored closely
within the first week of initiating therapy and periodically thereafter. ACE inhibitors and ARBs are
actually preferred in CKD for renoprotection but require monitoring for hyperkalemia as well.
11. A nurse practitioner is considering adding clonidine to a patient's antihypertensive
regimen. Which of the following is a critical prescribing consideration for clonidine?
A. Clonidine enhances the renin-angiotensin-aldosterone system, increasing angiotensin II levels
4
CHAMBERLAIN NR566 ADVANCED PHARMACOLOGY
FINAL EXAMINATION — 2026/2027
75 Questions | Advanced Pharmacology for MSN-FNP/AGPCNP | Next Generation NCLEX-Style
Total Questions: 75 | Testing Time: 120–150 Minutes | Passing Score: 75–80%
Instructions: This examination consists of 75 multiple-choice questions designed to assess advanced
pharmacology knowledge for nurse practitioner students. Each question has four answer choices (A
through D). Select the single best answer for each question. Questions cover pharmacokinetic and
pharmacodynamic principles, medication management across major organ systems, drug interactions,
adverse effects, and clinical decision-making. Use clinical judgment and evidence-based guidelines to guide
your responses. The correct answer and a detailed rationale follow each question.
1. A 55-year-old patient with hepatic cirrhosis is prescribed a medication that undergoes
extensive first-pass metabolism. Which pharmacokinetic alteration is most expected in this
patient?
A. Decreased volume of distribution leading to lower steady-state concentrations
B. Increased bioavailability due to reduced hepatic metabolism of the first-pass effect
C. Accelerated renal clearance requiring higher dosing intervals
D. Enhanced protein binding resulting in decreased free drug concentration
Correct Answer: B. Increased bioavailability due to reduced hepatic metabolism of the
first-pass effect
Rationale: First-pass metabolism occurs when a drug is extensively metabolized by the liver before
reaching systemic circulation. In hepatic cirrhosis, hepatocyte function is impaired, reducing the
first-pass effect and thereby increasing the bioavailability of the drug. This can lead to higher-than-
expected plasma concentrations and increased risk of toxicity, necessitating dosage reduction.
2. A nurse practitioner is prescribing a drug with a narrow therapeutic index. Which of the
following best defines therapeutic index (TI)?
A. The ratio of the effective dose for 99% of the population to the effective dose for 1% of the
population
B. The ratio of the median lethal dose (LD50) to the median effective dose (ED50), where a lower TI
indicates greater safety
C. The ratio of the median effective dose (ED50) to the median lethal dose (LD50), where a higher TI
indicates greater safety
D. The difference between the maximum tolerated dose and the minimum effective dose expressed in
milligrams
1
, NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
Correct Answer: C. The ratio of the median effective dose (ED50) to the median lethal
dose (LD50), where a higher TI indicates greater safety
Rationale: The therapeutic index is calculated as TD50 (or LD50) divided by ED50. A higher TI
indicates a wider margin of safety between the effective dose and the toxic dose. Drugs with a
narrow TI (e.g., warfarin, digoxin, lithium, phenytoin) require close therapeutic drug monitoring to
avoid toxicity.
3. A patient is taking a highly protein-bound drug (98% bound to albumin). A second drug
that also binds to albumin at the same site is added. What is the most likely pharmacokinetic
consequence?
A. No change in drug effect because only free drug is pharmacologically active
B. Displacement of the first drug from albumin binding sites, leading to a transient increase in free
(active) drug concentration and potential toxicity
C. Increased metabolism of the first drug due to increased hepatic blood flow
D. Decreased renal excretion of the first drug due to enhanced tubular reabsorption
Correct Answer: B. Displacement of the first drug from albumin binding sites, leading
to a transient increase in free (active) drug concentration and potential toxicity
Rationale: When two drugs compete for the same plasma protein binding site (typically albumin for
acidic drugs), the drug with higher affinity can displace the other, increasing the free (unbound)
fraction of the displaced drug. This transiently raises the pharmacologically active concentration,
potentially causing toxicity until the free drug is redistributed, metabolized, or excreted.
4. A drug has a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration with continuous dosing?
A. 12 hours (one half-life)
B. 24 hours (two half-lives)
C. 48 to 60 hours (four to five half-lives)
D. 84 hours (seven half-lives)
Correct Answer: C. 48 to 60 hours (four to five half-lives)
Rationale: Steady-state is achieved when the rate of drug administration equals the rate of
elimination. It takes approximately four to five half-lives to reach approximately 94% to 97% of
steady-state concentration. For a drug with a 12-hour half-life, steady-state is reached in 48 to 60
hours. A loading dose can achieve therapeutic levels more rapidly.
5. P-glycoprotein (P-gp) is an efflux transporter that plays a significant role in which of the
following pharmacokinetic processes?
A. Promoting drug absorption across the intestinal epithelium into systemic circulation
B. Pumping drugs out of cells back into the intestinal lumen, blood-brain barrier endothelial cells, and
renal tubules, thereby reducing bioavailability and enhancing excretion
C. Facilitating hepatic uptake of drugs for phase I metabolism
D. Enhancing protein binding of acidic drugs in the plasma compartment
2
, NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
Correct Answer: B. Pumping drugs out of cells back into the intestinal lumen, blood-
brain barrier endothelial cells, and renal tubules, thereby reducing bioavailability and
enhancing excretion
Rationale: P-glycoprotein is an ATP-dependent efflux transporter located on intestinal epithelium,
the blood-brain barrier, hepatocytes, and renal proximal tubule cells. It pumps substrates out of
cells, reducing intestinal drug absorption, limiting central nervous system penetration, and
promoting biliary and renal excretion. P-gp inhibitors (e.g., verapamil, clarithromycin) can
increase bioavailability of P-gp substrates.
6. Which of the following best describes the concept of volume of distribution (Vd)?
A. The actual physical volume within the body that a drug occupies, measured in liters
B. A theoretical pharmacokinetic parameter relating the total amount of drug in the body to the
plasma drug concentration, where a high Vd indicates extensive tissue distribution
C. The volume of blood plasma cleared of drug per unit time, expressed as mL/min
D. The concentration of drug at the site of action divided by the plasma concentration
Correct Answer: B. A theoretical pharmacokinetic parameter relating the total amount
of drug in the body to the plasma drug concentration, where a high Vd indicates
extensive tissue distribution
Rationale: Volume of distribution (Vd) is a theoretical proportionality constant defined as Vd = total
amount of drug in body / plasma drug concentration. A high Vd (>42 L in adults) suggests extensive
tissue distribution (e.g., lipophilic drugs like digoxin), while a low Vd suggests the drug remains
largely in the plasma compartment (e.g., warfarin, which is highly protein-bound).
7. A 48-year-old African American patient with type 2 diabetes mellitus and hypertension
has a blood pressure of 148/94 mmHg. According to the ACC/AHA guidelines, which of the
following first-line antihypertensive classes is most appropriate?
A. ACE inhibitor monotherapy as the sole initial agent
B. Calcium channel blocker or thiazide diuretic, either as initial monotherapy or as part of
combination therapy
C. Beta-blocker as first-line monotherapy to achieve glycemic control
D. Alpha-blocker to address both blood pressure and diabetic neuropathy symptoms
Correct Answer: B. Calcium channel blocker or thiazide diuretic, either as initial
monotherapy or as part of combination therapy
Rationale: The ACC/AHA 2017 guidelines recommend initial antihypertensive treatment with a
thiazide diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. In African American
patients, CCBs and thiazide diuretics are generally more effective as first-line agents than ACE
inhibitors or ARBs. For patients with diabetes, an ACE inhibitor or ARB is often added for renal
protection, but CCBs and thiazides are effective for BP control in this population.
8. A 62-year-old patient is started on lisinopril for hypertension. The nurse practitioner
should counsel the patient to report which of the following findings, which may indicate a
potentially serious adverse effect?
A. Mild, dry, nonproductive cough that is persistent
3
, NR566 Advanced Pharmacology Final Exam — Chamberlain 2026/2027
B. Swelling of the lips, tongue, or throat suggesting angioedema
C. Transient dizziness upon standing that resolves after a few minutes
D. Mild increase in serum potassium from 4.0 to 4.8 mEq/L
Correct Answer: B. Swelling of the lips, tongue, or throat suggesting angioedema
Rationale: Although a dry cough is the most common side effect of ACE inhibitors (occurring in up to
20% of patients), angioedema is the most serious and potentially life-threatening adverse effect,
occurring in 0.1% to 0.7% of patients. It involves swelling of the face, lips, tongue, and throat, which
can compromise the airway. ACE inhibitors should be discontinued immediately and the patient
should seek emergency care. Angioedema is more common in African American patients.
9. A patient with hypertension and benign prostatic hyperplasia (BPH) is prescribed
doxazosin. What is the most important safety consideration when initiating this medication?
A. Monitoring for reflex tachycardia and palpitations at therapeutic doses
B. Instructing the patient to take the first dose at bedtime to minimize the risk of first-dose
hypotension and syncope
C. Obtaining baseline liver function tests and monitoring for hepatotoxicity
D. Avoiding concurrent use with potassium-sparing diuretics due to hyperkalemia risk
Correct Answer: B. Instructing the patient to take the first dose at bedtime to minimize
the risk of first-dose hypotension and syncope
Rationale: Alpha-1 blockers (e.g., doxazosin, prazosin, terazosin) are associated with first-dose
hypotension, which can cause syncope and falls. The risk is highest with the initial dose and dose
increases. Patients should take the first dose at bedtime and rise slowly from sitting or supine
positions. Alpha-1 blockers are also used for BPH because they relax smooth muscle in the prostate
and bladder neck.
10. A 70-year-old patient with stage 2 hypertension and chronic kidney disease (CKD) stage
3a (eGFR 45 mL/min) is being evaluated for antihypertensive therapy. Which of the
following agents requires the most cautious use or dose adjustment in this patient?
A. Losartan (ARB), which provides renoprotective benefits in CKD
B. Amlodipine (CCB), which has minimal renal metabolism
C. Spironolactone (potassium-sparing diuretic), which poses a high risk of hyperkalemia in CKD
D. Lisinopril (ACE inhibitor), which should be avoided entirely in all stages of CKD
Correct Answer: C. Spironolactone (potassium-sparing diuretic), which poses a high
risk of hyperkalemia in CKD
Rationale: Spironolactone is a potassium-sparing diuretic that blocks aldosterone receptors. In
patients with CKD, the already reduced ability to excrete potassium places them at significantly
increased risk of hyperkalemia. Serum potassium and renal function must be monitored closely
within the first week of initiating therapy and periodically thereafter. ACE inhibitors and ARBs are
actually preferred in CKD for renoprotection but require monitoring for hyperkalemia as well.
11. A nurse practitioner is considering adding clonidine to a patient's antihypertensive
regimen. Which of the following is a critical prescribing consideration for clonidine?
A. Clonidine enhances the renin-angiotensin-aldosterone system, increasing angiotensin II levels
4
